Search

Summary: Intravenous Anti‐Rhesus‐D immunoglobulin (Anti‐D) is a first‐line treatment option for immune thrombocytopenia in non‐splenectomised and RhD‐positive patients. In this report, we retrospectively review our experience with intramuscular (IM) Anti‐D treatment in 74 adult patients between 1990 and 2018. We found that 73% of patients showed a response; almost all of them had complete responses (68.9%), and 26% achieved complete responses sustained at least 6 months after treatment discontinuation. [Correction added on 02 December 2022, after first online publication: In the preceding sentence, '(68.89%)' has been corrected to '(68.9%)' in this version.] No significant side effects were observed with no cases of acute haemolysis or anaemia reported. We conclude from this study that IM Anti‐D is an effective and safe treatment for immune thrombocytopenia. [ABSTRACT FROM AUTHOR]

Objective To describe the reasons for and result of thrombopoietin receptor agonists ( TPO- RA) switching in adult immune thrombocytopenia ( ITP) patients of 4 Spanish centres. Methods We retrospectively analysed all patients who received sequential treatment with both TPO- RA between 2010 and 2015 recording clinical and biological parameters. Results Twenty-six patients were included; 17 received first romiplostim and 9 received first eltrombopag. Reasons for switching were inefficacy (n = 10), patient preference (n = 8), side effects (n = 5) and excessive platelet count fluctuation (n = 3). When the switch was due to inefficacy, 100% of patients who received romiplostim first and 66% who received eltrombopag first responded to the second drug. It is significant that none of the patients who received romiplostim first reached the maximum recommended dose before switching. When the change was due to patient preference or because of side effects, 100% of the patients responded to both TPO- RA. Three patients changed from romiplostim to eltrombopag due to platelet count fluctuation; one did not respond and the fluctuation persisted in the remaining 2 patients. We also found 4 sustained remissions after administering the second TPO- RA, 2 of these with inefficacy of the first drug. Conclusion TPO- RA switching is a feasible strategy in different scenarios with high probability of success. [ABSTRACT FROM AUTHOR]